Search the Newsreel

Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-08-10

Puma Biotechnology reported strong Q2 2026 financial results, with total revenue reaching $56.5 million, primarily driven by increased demand for NERLYNX. The company is now debt-free after repaying its Athyrium loan and has raised its full-year guidance for both product revenue and net income. …

Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades

Puma Biotechnology (PBYI) saw its stock jump 9.7% after reporting strong Q2 2026 earnings, driven by NERLYNX revenue and increased net income. While current profitability and raised full-year guidance are positive, analysts project weaker earnings in the future, creating a tension between present strength …

Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results, Beats Expectations By $0.15 EPS

Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Puma Biotechnology Inc (PBYI) currently holds an earnings forecast score of 6.00, placing it 130th out of 156 companies in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for PBYI, with a range from $2.00 to $7.00. The company's next …

TD Cowen Forecasts Strong Price Appreciation for Puma Biotechnology (NASDAQ:PBYI) Stock

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Puma Biotechnology, Inc. announced its financial results for the second quarter and six months ending June 30, 2026. For the second quarter, the company saw an increase in revenue to USD 56.5 million and net income rose to USD 8.19 million. However, for the …

PUMA BIOTECHNOLOGY, INC. 2026: Revenue $56.5M, EPS $0.16— 10-Q Summary

PUMA BIOTECHNOLOGY, INC. reported strong quarterly results for 2026, with revenue reaching $56.5 million and diluted EPS of $0.16, demonstrating significant year-over-year growth. Revenue growth was driven by increased volume in core product lines and a shift towards e-commerce, while operational improvements helped streamline …

Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ...

Puma Biotechnology Inc. (PBYI) reported strong Q2 2026 results, becoming debt-free and raising its full-year revenue and net income guidance. The company saw significant growth in NERLYNX sales and is advancing its alisertib clinical program, planning for new Phase III trials in 2027. Despite …

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

Earnings call transcript: Puma Biotechnology tops Q2 2026 estimates as profit returns

Puma Biotechnology (PBYI) exceeded Q2 2026 revenue and earnings estimates, reporting $56.5 million in revenue and $0.16 GAAP EPS, driven by strong NERLYNX sales. The company returned to profitability after a prior quarter loss and raised its full-year 2026 guidance for net product revenue …

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - August 5, 2026

Puma Biotechnology, Inc. announced the grant of inducement restricted stock unit awards covering 35,375 shares of common stock to five new non-executive employees on August 3, 2026. These awards, granted under the company's 2017 Employment Inducement Incentive Award Plan, vest over a three-year period …

Puma Biotechnology (PBYI) Earnings Date and Reports 2026

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results

Puma Biotechnology, Inc. will host a conference call on Thursday, February 26, 2026, at 1:30 p.m. PT/4:30 p.m. ET to discuss its fourth quarter and full year 2025 financial results. The call details and webcast information are provided for investors and interested parties. The …

Renaissance Technologies LLC Cuts Position in Puma Biotechnology, Inc. $PBYI

Renaissance Technologies LLC reduced its stake in Puma Biotechnology (PBYI) by 8.5% in the first quarter of 2026, selling 181,400 shares but still retaining 1.94 million shares valued at approximately $12.4 million. Despite cautious analyst sentiment and insider share sales totaling $1.01 million in …

Puma Biotechnology Inc (PBYI) Valuation: PE, PB & Fair Value Analysis

Puma Biotechnology Inc (PBYI) has a current valuation score of 5.76, ranking 143 out of 155 in the Pharmaceuticals industry. The company's current P/E ratio is 15.75, which is significantly below its recent high but above its recent low. However, relevant data for P/B, …

Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline

Puma Biotech (PBYI) is expected to report a year-over-year decline in Q2 earnings despite higher revenues for the quarter ended June 2026. The company is projected to post earnings of $0.10 per share, a 33.3% decrease, on revenues of $53.17 million, up 1.5%. Analysts …

Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday

Puma Biotechnology Inc (PBYI) Institutional Confidence

Puma Biotechnology Inc (PBYI) has an institutional shareholding score of 7.00, placing it 50th among 155 companies in the Pharmaceuticals industry. The institutional shareholding proportion is 81.56%, marking a 14.60% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 3.82% of outstanding shares.

PBYI|Puma Biotechnology Inc|Price:7.955|Chg%:-0.035

Puma Biotechnology Inc (PBYI) has strong fundamentals and high growth potential, with its valuation considered fairly valued within the Pharmaceuticals industry. The stock exhibits high institutional ownership and analysts generally rate it as a Hold, with expectations for stable price performance in the medium …

Puma Biotechnology Inc Revenue Breakdown – NASDAQ:PBYI

Puma Biotechnology Inc. (NASDAQ: PBYI) generated 204.10 million USD in revenue last year. Its top-performing segment, Cancer Care Products, contributed 228.37 million USD, which was slightly down from 230.47 million USD the previous year. The United States was the primary source of revenue, accounting …

Puma Biotechnology Inc (PBYI) Financial Health: Profitability & Balance Sheet Analysis

Puma Biotechnology Inc (PBYI) has a current financial score of 7.61, indicating robust financial status and high operating efficiency, ranking 108 out of 155 in the Pharmaceuticals industry. The company's latest quarterly revenue was $44.81M, showing a 2.59% year-over-year decrease, while net profit decreased …

Puma Biotechnology Inc (PBYI) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a historical overview of dividends and stock splits for Puma Biotechnology Inc (PBYI). It indicates that the company has not distributed any dividends over the past five years, with "No Data" appearing for dividend history. The document also presents current stock …

Puma Biotechnology Inc (PBYI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Puma Biotechnology Inc's (PBYI) shareholder structure, detailing major individual and institutional holders as of recent updates. It includes a breakdown of shareholder types, institutional shareholding trends over recent quarters, and recent shareholder activity, alongside related ETF holdings.

ETFs Investing in Puma Biotechnology, Inc. Stocks

This article lists various ETFs that hold shares of Puma Biotechnology, Inc. (PBYI). The ETFs are primarily focused on small-cap, value, or biotechnology sectors and include details such as market value, weight of PBYI stock in the fund, issuer, management style, expense ratio, and …

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

Puma Biotechnology, Inc. announced it will host a conference call on Thursday, August 6, 2026, at 1:30 p.m. PT/4:30 p.m. ET to discuss its second-quarter 2026 financial results. The call will follow the release of these results and will include a live webcast and …

Puma Biotechnology Inc (PBYI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Puma Biotechnology Inc (PBYI), detailing its price momentum, support and resistance levels, and various technical indicators. It notes that PBYI's current price momentum score is 3.31, with the stock trading between a resistance level of 8.62 and …

Puma Biotechnology will webcast its Q2 results Aug. 6

Puma Biotechnology awards stock to four new employees

PBYI Forecast — Price Target — Prediction for 2027

Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why

There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings

Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings